Sertraline and Cerebral atrophy - a phase IV clinical study of FDA data
Summary:
Cerebral atrophy is found among people who take Sertraline, especially for people who are female, 60+ old, have been taking the drug for < 1 month.
The phase IV clinical study analyzes which people take Sertraline and have Cerebral atrophy. It is created by eHealthMe based on reports of 123,363 people who have side effects when taking Sertraline from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
123,363 people reported to have side effects when taking Sertraline.
Among them, 101 people (0.08%) have Cerebral atrophy.
What is Sertraline?
Sertraline has active ingredients of sertraline hydrochloride. It is often used in depression. eHealthMe is studying from 129,608 Sertraline users for its effectiveness, alternative drugs and more.
What is Cerebral atrophy?
Cerebral atrophy (decrement in size of brain) is found to be associated with 1,502 drugs and 828 conditions by eHealthMe.
Number of Sertraline and Cerebral atrophy reports submitted per year:

Time on Sertraline when people have Cerebral atrophy *:
Gender of people who have Cerebral atrophy when taking Sertraline*:
Age of people who have Cerebral atrophy when taking Sertraline *:
Common drugs people take besides Sertraline *:
Common side effects people have besides Cerebral atrophy *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Sertraline and have Cerebral atrophy?
Check whether Cerebral atrophy is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Izgi C, Erdem G, Mansuroglu D, Kurtoglu N, Kara M, Gunesdogdu F, "Severe hypokalemia probably associated with sertraline use", Annals of Pharmacotherapy, 2014 Jan .
Related studies
How severe was Cerebral atrophy and when was it recovered:
Expand to all the drugs that have ingredients of sertraline hydrochloride:
Alternative drugs to, pros and cons of Sertraline:
- Sertraline (129,608 reports)
Common Sertraline side effects:
- Fatigue (feeling of tiredness): 7,796 reports
- Drug ineffective: 7,435 reports
- Stress and anxiety: 6,629 reports
- Diarrhea: 6,162 reports
- Dizziness: 6,109 reports
- Headache (pain in head): 6,097 reports
Browse all side effects of Sertraline:
a b c d e f g h i j k l m n o p q r s t u v w x y zCerebral atrophy treatments and more:
- Cerebral atrophy (5,656 reports)
COVID vaccines that are related to Cerebral atrophy:
- Cerebral atrophy in Moderna COVID Vaccine
- Cerebral atrophy in Pfizer BioNTech Covid Vaccine
- Cerebral atrophy in Johnson and Johnson Covid Vaccine
Common drugs associated with Cerebral atrophy:
- Aspirin: 514 reports
- Zometa: 455 reports
- Prednisone: 436 reports
- Aredia: 395 reports
- Vioxx: 351 reports
- Lasix: 325 reports
- Coumadin: 322 reports
- Lisinopril: 301 reports
- Fosamax: 300 reports
- Prilosec: 251 reports
All the drugs that are associated with Cerebral atrophy:
- Cerebral atrophy (1,502 drugs)
Common conditions associated with Cerebral atrophy:
- Multiple sclerosis: 434 reports
- High blood pressure: 366 reports
- Depression: 329 reports
- Osteoporosis: 252 reports
- Pain: 229 reports
- Multiple myeloma: 191 reports
- Epilepsy: 169 reports
All the conditions that are associated with Cerebral atrophy:
- Cerebral atrophy (828 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on sertraline hydrochloride (the active ingredients of Sertraline) and Sertraline (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Cosopt and Nuplazid drug interaction - a second ago
- Zovia 1/35E-28 vs. Skyla - 5 seconds ago
- Amlodipine and Nephropathy Toxic - 12 seconds ago
- Zolpidem and Complex Regional Pain Syndrome - 13 seconds ago
- Concerta and Hydroxyzine drug interaction - 16 seconds ago
- Zoloft and Eye Redness - 25 seconds ago
- Amlodipine Besylate and Clopidogrel drug interaction - 28 seconds ago
- Bextra and Zoloft drug interaction - 33 seconds ago
- Climara and Restasis drug interaction - 35 seconds ago
- Weight Loss and Stent Occlusion - 36 seconds ago